Evidence map›Paper›PMID 42106953›Full record

ArticlemAbs2026

Discovery, development, and characterization of SPY002 and SPY072, two novel extended half-life monoclonal antibodies targeting TL1A: in vitro properties, in vivo pharmacology, pharmacokinetics, and preclinical safety.

Matthew Siegel, Eric Zhu, Daniel Rios, Byong H Kang, Justin McNally, Michael Kennedy, Kinjal Hew, Preeyam Patel, Olivia Ballew, David H Giles and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Matthew SiegelSpyre Therapeutics, Waltham, MA, USA.
Eric ZhuParagon Therapeutics, Waltham, MA, USA.
Daniel RiosParagon Therapeutics, Waltham, MA, USA.
Byong H KangParagon Therapeutics, Waltham, MA, USA.
Justin McNallySpyre Therapeutics, Waltham, MA, USA.
Michael KennedySpyre Therapeutics, Waltham, MA, USA.
Kinjal HewSpyre Therapeutics, Waltham, MA, USA.
Preeyam PatelSpyre Therapeutics, Waltham, MA, USA.
Olivia BallewSpyre Therapeutics, Waltham, MA, USA.
David H GilesSpyre Therapeutics, Waltham, MA, USA.
Emily M A LewisSpyre Therapeutics, Waltham, MA, USA.
Justin LaFountaineSpyre Therapeutics, Waltham, MA, USA.
Jason OhParagon Therapeutics, Waltham, MA, USA.
Joshua R FriedmanSpyre Therapeutics, Waltham, MA, USA.
Mark J RoseSpyre Therapeutics, Waltham, MA, USA.
Hussam ShaheenParagon Therapeutics, Waltham, MA, USA.
Andrew G SpencerSpyre Therapeutics, Waltham, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TL1A is a proinflammatory cytokine in the tumor necrosis factor (TNF) superfamily that signals via DR3 on T helper cells, innate lymphoid cells, and fibroblasts. Dysregulated TL1A signaling has been hypothesized to affect multiple immune-mediated diseases, with clinical proof of concept demonstrated in ulcerative colitis and Crohn's disease. We characterized the binding affinity, specificity, structure, pharmacodynamics, pharmacokinetics, and toxicity profiles of SPY002 and SPY072, two novel extended half-life monoclonal antibodies that inhibit TL1A. SPY002 and SPY072 demonstrated selective, high-affinity binding to human TL1A (K

Indexed as

Antibodies, MonoclonalTumor Necrosis Factor Ligand Superfamily Member 15AnimalsFemaleHalf-LifeHumansMacaca fascicularisMaleMiceRatsAntibodies, MonoclonalTNFSF15 protein, humanTumor Necrosis Factor Ligand Superfamily Member 15Extended half-lifeinflammatory bowel diseasemonoclonal antibodypharmacodynamicspharmacokineticsrheumatic diseasesSPY002SPY072TL1A

Identifiers

PMID42106953
PMCPMC13166218

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.